Artia Global Partners’s Q32 Bio QTTB Stock Holding History

Artia Global Partners’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,705	Closed	-$210K	–	57
2024 Q3	$210K	Buy	+4,705	New	+$173K	0.06%	45

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Artia Global Partners's QTTB Position: Q4 2024 in Review

Artia Global Partners sold out of Q32 Bio (QTTB) in Q4 2024, closing a stake of 4,705 shares — an estimated $210K sold.

Artia Global Partners first reported a position in QTTB in Q3 2024 and held it in 1 quarter. The position peaked at $210K in Q3 2024. 92 funds tracked by Wall St. Rank hold QTTB as of Q4 2024.

Artia Global Partners reported no remaining Q32 Bio position as of Q4 2024 after selling out during the quarter.
Artia Global Partners sold 4,705 Q32 Bio shares in Q4 2024, an estimated $210K.
Artia Global Partners first reported a position in Q32 Bio in Q3 2024 and held it in 1 quarter.
Artia Global Partners's Q32 Bio position peaked at $210K in Q3 2024.
92 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2024.

Based on Artia Global Partners's 13F filing for Q4 2024, filed 14 Feb 2025.